Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene to Test its Bispecific with Celularity’s Stem Cell Natural Killer Cell Therapy

publication date: Jul 19, 2022

Shanghai Antengene will conduct preclinical tests that combine its bispecific with a cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy developed by New Jersey’s Celularity. Celularity develops allogeneic cryopreserved, off-the-shelf cell therapies that include unmodified NK cells, genetically-modified NK cells, CAR T-cells and mesenchymal-like adherent stromal cells (ASCs). They target indications in cancer, infectious and degenerative diseases. Antengene is developing a PD-L1/4-1BB bispecific candidate, which has been approved to start US trials for solid tumors and Non-Hodgkin lymphoma. More details....

Stock Symbols: (HK: 6996) (NSDQ: CELU)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital